OCGN – Ocugen, Inc.
Ocugen, Inc.OCGN
$0.68Name : Ocugen, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $197,843,968.00
EPSttm : -0.19
Ocugen, Inc.
$0.68
2.88%$0.0202Float Short %
20.61
Margin Of Safety %
Put/Call OI Ratio
0.05
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
-0.07
Price
0.68
Target Price
6.5
Analyst Recom
1
Performance Q
-25.37
Relative Volume
0.55
Beta
3.87
Ticker: OCGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | OCGN | 0.7742 | 0.05 | 0.00 | 27287 |
| 2025-01-24 | OCGN | 0.7748 | 0.05 | 0.02 | 27861 |
| 2025-01-27 | OCGN | 0.7306 | 0.05 | 0.01 | 28575 |
| 2025-01-28 | OCGN | 0.7152 | 0.05 | 0.02 | 28944 |
| 2025-01-29 | OCGN | 0.733 | 0.05 | 0.01 | 29243 |
| 2025-01-30 | OCGN | 0.7656 | 0.05 | 0.01 | 29627 |
| 2025-01-31 | OCGN | 0.7317 | 0.05 | 0.05 | 29961 |
| 2025-02-03 | OCGN | 0.7236 | 0.05 | 0.03 | 29883 |
| 2025-02-04 | OCGN | 0.7393 | 0.05 | 0.05 | 29987 |
| 2025-02-05 | OCGN | 0.7506 | 0.05 | 0.11 | 30232 |
| 2025-02-06 | OCGN | 0.7269 | 0.05 | 0.02 | 30354 |
| 2025-02-07 | OCGN | 0.7105 | 0.05 | 0.01 | 31140 |
| 2025-02-10 | OCGN | 0.7082 | 0.05 | 0.02 | 31301 |
| 2025-02-11 | OCGN | 0.6729 | 0.05 | 0.14 | 31804 |
| 2025-02-12 | OCGN | 0.6681 | 0.05 | 0.10 | 32027 |
| 2025-02-13 | OCGN | 0.6986 | 0.05 | 0.05 | 32340 |
| 2025-02-14 | OCGN | 0.7106 | 0.05 | 0.01 | 32608 |
| 2025-02-18 | OCGN | 0.7292 | 0.05 | 0.04 | 33314 |
| 2025-02-19 | OCGN | 0.6869 | 0.05 | 0.48 | 33428 |
| 2025-02-20 | OCGN | 0.7 | 0.05 | 0.00 | 33533 |
| 2025-02-21 | OCGN | 0.68 | 0.05 | 0.01 | 33607 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | OCGN | 0.78 | -88.9 | -20.8 | -0.19 |
| 2025-01-24 | OCGN | 0.78 | -88.9 | -17.8 | -0.19 |
| 2025-01-27 | OCGN | 0.73 | -88.9 | -13.0 | -0.19 |
| 2025-01-28 | OCGN | 0.71 | -88.9 | -15.6 | -0.19 |
| 2025-01-29 | OCGN | 0.74 | -88.9 | -21.2 | -0.19 |
| 2025-01-30 | OCGN | 0.77 | -88.9 | -21.5 | -0.19 |
| 2025-01-31 | OCGN | 0.73 | -88.9 | -14.0 | -0.19 |
| 2025-02-03 | OCGN | 0.72 | -88.9 | -17.2 | -0.19 |
| 2025-02-04 | OCGN | 0.74 | -88.9 | -20.3 | -0.19 |
| 2025-02-05 | OCGN | 0.75 | -88.9 | -18.5 | -0.19 |
| 2025-02-06 | OCGN | 0.73 | -88.9 | -15.4 | -0.19 |
| 2025-02-07 | OCGN | 0.71 | -88.9 | -16.7 | -0.19 |
| 2025-02-10 | OCGN | 0.70 | -88.9 | -16.8 | -0.19 |
| 2025-02-11 | OCGN | 0.67 | -88.9 | -15.9 | -0.19 |
| 2025-02-12 | OCGN | 0.66 | -88.9 | -18.6 | -0.19 |
| 2025-02-13 | OCGN | 0.70 | -88.9 | -25.3 | -0.19 |
| 2025-02-14 | OCGN | 0.72 | -88.9 | - | -0.19 |
| 2025-02-18 | OCGN | 0.73 | -88.9 | - | -0.19 |
| 2025-02-19 | OCGN | 0.70 | -88.9 | - | -0.19 |
| 2025-02-20 | OCGN | 0.70 | -88.9 | - | -0.19 |
| 2025-02-21 | OCGN | 0.68 | -77.8 | - | -0.19 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | OCGN | 0.67 | 18.26 | 18.27 |
| 2025-01-24 | OCGN | 0.67 | 18.26 | 18.27 |
| 2025-01-27 | OCGN | 0.67 | 18.23 | 18.27 |
| 2025-01-28 | OCGN | 0.67 | 18.23 | 19.61 |
| 2025-01-29 | OCGN | 0.67 | 18.23 | 19.61 |
| 2025-01-30 | OCGN | 0.67 | 18.23 | 19.61 |
| 2025-01-31 | OCGN | 0.67 | 18.23 | 19.61 |
| 2025-02-03 | OCGN | 0.67 | 17.93 | 19.61 |
| 2025-02-04 | OCGN | 0.67 | 17.93 | 19.61 |
| 2025-02-05 | OCGN | 0.67 | 17.93 | 19.61 |
| 2025-02-06 | OCGN | 0.67 | 17.93 | 19.64 |
| 2025-02-07 | OCGN | 0.67 | 17.93 | 19.64 |
| 2025-02-10 | OCGN | 0.67 | 22.09 | 19.64 |
| 2025-02-11 | OCGN | 0.67 | 22.09 | 19.64 |
| 2025-02-12 | OCGN | 0.67 | 22.09 | 20.61 |
| 2025-02-13 | OCGN | 0.67 | 22.09 | 20.61 |
| 2025-02-14 | OCGN | 0.67 | 22.09 | 20.61 |
| 2025-02-18 | OCGN | 0.67 | 4.19 | 20.61 |
| 2025-02-19 | OCGN | 0.67 | 4.19 | 20.61 |
| 2025-02-20 | OCGN | 0.67 | 4.19 | 20.61 |
| 2025-02-21 | OCGN | 0.67 | 4.19 | 20.61 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.05
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-0.06
Insider Transactions
0.67
Institutional Transactions
4.19
Beta
3.87
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
14
Growth Score
21
Sentiment Score
71
Actual DrawDown %
96.4
Max Drawdown 5-Year %
-97.7
Target Price
6.5
P/E
Forward P/E
PEG
P/S
42.09
P/B
4.86
P/Free Cash Flow
EPS
-0.18
Average EPS Est. Cur. Y
-0.19
EPS Next Y. (Est.)
-0.26
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-982.04
Relative Volume
0.55
Return on Equity vs Sector %
-145.1
Return on Equity vs Industry %
-129.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
Ocugen, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 65
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
stock quote shares OCGN – Ocugen, Inc. Stock Price stock today
news today OCGN – Ocugen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCGN – Ocugen, Inc. yahoo finance google finance
stock history OCGN – Ocugen, Inc. invest stock market
stock prices OCGN premarket after hours
ticker OCGN fair value insiders trading